OLMA
Olema Pharmaceuticals IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.37B
P/E Ratio
—
EPS
$-1.87
Beta
2.18
52W High
$36.26
52W Low
$3.30
50-Day MA
$20.52
200-Day MA
$14.81
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Olema Pharmaceuticals Inc
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company is headquartered in San Francisco, California.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-168.21M |
| Operating Margin | 0.00% |
| Return on Equity | -36.60% |
| Return on Assets | -21.40% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $5.88 |
| Price-to-Book | 2.74 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -3.33 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $87.16M |
| Float | $67.43M |
| % Insiders | 1.97% |
| % Institutions | 101.07% |
Analyst Ratings
Consensus ($43.00 target)
2
Strong Buy10
BuyData last updated: 4/9/2026